ADC Therapeutics SA (NYSE:ADCT) shares traded lower over the last trading session, losing -0.26% on 02/12/21. The shares fell to a low of $29.46 before closing at $30.47. Intraday shares traded counted 72185.0, which was 71.93% higher than its 30-day average trading volume of 257.16K. ADCT’s previous close was $30.55 while the outstanding shares total 76.72M. The firm The stock’s Relative Strength Index (RSI) is 47.48, with weekly volatility at 5.61% and ATR at 1.88. The ADCT stock’s 52-week price range has touched low of $25.10 and a $56.59 high.
Investors have identified the Biotechnology company ADC Therapeutics SA as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.34 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
ADC Therapeutics SA (ADCT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For ADCT, the company has in raw cash 494.42 million on their books with 2.64 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 506.42 million total, with 32.56 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -2.79 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ADCT sounds very interesting.
Is the stock of ADCT attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 48.05%.
5 out of 6 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on ADC Therapeutics SA. 0 analysts has assigned a Sell rating on the ADCT stock. The 12-month mean consensus price target for the company’s shares has been set at $48.75.